Taysha Gene Therapies
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2020-01-01
- Employees
- 52
- Market Cap
- $438.5M
- Website
- http://www.tayshagtx.com
Taysha Gene Therapies Advances TSHA-102 for Rett Syndrome with FDA Alignment on Pivotal Trial Design
Taysha Gene Therapies has received FDA alignment on key elements of the TSHA-102 pivotal trial design for Rett syndrome, with the agency advising direct submission of trial protocol as an IND amendment, potentially expediting study initiation.
Rett Syndrome Pipeline Analysis Reveals 20+ Companies Developing Novel Therapeutics with Gene Therapy Leading Innovation
A comprehensive 2025 pipeline analysis identifies over 20 companies developing more than 20 therapeutic candidates for Rett syndrome, highlighting significant industry investment in this rare neurological disorder.
FDA Leadership Shakeup: Peter Marks' Forced Resignation Sends Shockwaves Through Biopharma Industry
Peter Marks, head of FDA's Center for Biologics Evaluation and Research since 2016, was forced to resign after refusing to support HHS Secretary Robert F. Kennedy Jr.'s vaccine safety claims.
Neurogene Halts High-Dose Arm of Rett Syndrome Gene Therapy Trial Following Serious Adverse Event
Neurogene has suspended enrollment in the high-dose arm of its NGN-401 gene therapy trial for Rett syndrome after a patient developed life-threatening systemic hyperinflammatory syndrome, a known risk with AAV vector therapies.
Gene Therapies Show Promise in Targeting the Root Cause of Rett Syndrome
Two companies, Neurogene and Taysha Gene Therapies, are in Phase 1/2 clinical trials with gene therapies targeting the MECP2 gene for Rett syndrome.
Neurogene's Rett Syndrome Gene Therapy Trial Pauses High Dose After Patient Death
A patient with Rett syndrome died after receiving a high dose of Neurogene's experimental gene therapy, NGN-401, triggering a safety review.
Taysha Gene Therapies' TSHA-102 Shows Promise in Rett Syndrome Trials, Receives FDA Approval
Taysha Gene Therapies reported positive updates on its TSHA-102 program for Rett syndrome, with high dose treatment showing good tolerability in trials.
Neurogene's Rett Syndrome Gene Therapy Trial Paused After Serious Adverse Event
Neurogene's stock plummeted after disclosing a serious adverse event in a patient receiving a high dose of NGN-401, its gene therapy for Rett syndrome.
Gene Therapy Clinical Trial Pipeline Surges with Over 180 Companies Leading Innovation
The gene therapy market is experiencing substantial growth, fueled by technological advancements, increased investments, and a deeper understanding of genetic diseases.
Taysha's TSHA-102 Gene Therapy Shows Promise in Rett Syndrome Trials
Taysha Gene Therapies is evaluating TSHA-102, an AAV-based gene therapy, in Phase 1/2 REVEAL trials for both adolescent/adult and pediatric patients with Rett syndrome.